Join the Onpattro group to help and get support from people like you.
Onpattro News
Patisiran Can Preserve Functional Capacity in ATTR Amyloidosis
THURSDAY, Oct. 26, 2023 – For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved...
FDA Approves Onpattro (patisiran) Targeted RNA-based Therapy for Polyneuropathy Caused by hATTR
August 10, 2018 – The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary...
Ask a question
To post your own question to this support group, sign in or create an account.